Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & Administrative
Others
Ratios

SELLAS Life Sciences (SLS) Shares Outstanding (Diluted Average) (2020 - 2024)

SELLAS Life Sciences (SLS) has disclosed Shares Outstanding (Diluted Average) for 5 consecutive years, with $56.9 million as the latest value for Q3 2024.

  • Quarterly Shares Outstanding (Diluted Average) rose 100.81% to $56.9 million in Q3 2024 from the year-ago period, while the trailing twelve-month figure was $56.9 million through Sep 2024, up 100.81% year-over-year, with the annual reading at $27.8 million for FY2023, 43.21% up from the prior year.
  • Shares Outstanding (Diluted Average) for Q3 2024 was $56.9 million at SELLAS Life Sciences, down from $57.6 million in the prior quarter.
  • The five-year high for Shares Outstanding (Diluted Average) was $57.6 million in Q2 2024, with the low at $6.5 million in Q2 2020.
  • Average Shares Outstanding (Diluted Average) over 5 years is $23.5 million, with a median of $19.8 million recorded in 2022.
  • The sharpest move saw Shares Outstanding (Diluted Average) skyrocketed 130.28% in 2021, then grew 6.86% in 2022.
  • Over 5 years, Shares Outstanding (Diluted Average) stood at $8.0 million in 2020, then soared by 94.07% to $15.5 million in 2021, then rose by 25.29% to $19.4 million in 2022, then soared by 43.21% to $27.8 million in 2023, then soared by 104.99% to $56.9 million in 2024.
  • According to Business Quant data, Shares Outstanding (Diluted Average) over the past three periods came in at $56.9 million, $57.6 million, and $44.8 million for Q3 2024, Q2 2024, and Q1 2024 respectively.